VistaGen Therapeutics (NASDAQ:VTGN) Share Price Passes Below 50 Day Moving Average – Here’s What Happened

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.39 and traded as low as $0.64. VistaGen Therapeutics shares last traded at $0.6627, with a volume of 1,373,480 shares changing hands.

Key VistaGen Therapeutics News

Here are the key news stories impacting VistaGen Therapeutics this week:

• Negative Sentiment: Levi & Korsinsky filed a securities class action on behalf of VTGN shareholders alleging losses in the April 1, 2024–December 16, 2025 period; lead‑plaintiff deadline noted. Levi & Korsinsky Announcement
• Negative Sentiment: Rosen Law Firm announced a class action and is soliciting investors to seek lead‑plaintiff status for the same class period, increasing competing claims. Rosen Law Firm Notice
• Negative Sentiment: Bronstein, Gewirtz & Grossman filed a class action and is urging affected Vistagen investors to act, citing alleged securities law violations. Bronstein Filing
• Negative Sentiment: Bernstein Liebhard issued a deadline alert for investors who purchased VTGN during the alleged class period to join the litigation, signaling multiple firms pursuing claims. Bernstein Liebhard Alert
• Negative Sentiment: Faruqi & Faruqi is investigating claims and reminding investors of the March 16, 2026 lead‑plaintiff deadline, adding to litigation momentum. Faruqi & Faruqi Notice
• Negative Sentiment: Portnoy Law Firm and The Gross Law Firm similarly announced class actions/alerts, indicating multiple independent suits and plaintiff recruitment efforts. Portnoy Filing Gross Law Firm Alert

Analyst Upgrades and Downgrades

VTGN has been the subject of a number of research reports. Maxim Group reaffirmed a “hold” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Stifel Nicolaus downgraded shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.90 target price (down from $15.00) on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Finally, Wall Street Zen cut VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Four analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Stock Up 4.5%

The firm’s 50 day simple moving average is $2.39 and its 200 day simple moving average is $3.03. The company has a market cap of $26.17 million, a price-to-earnings ratio of -0.35 and a beta of 0.31.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The company had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.16 million. Analysts anticipate that VistaGen Therapeutics, Inc. will post -1.77 EPS for the current fiscal year.

Hedge Funds Weigh In On VistaGen Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Two Sigma Investments LP raised its position in shares of VistaGen Therapeutics by 223.5% during the 3rd quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock worth $1,027,000 after buying an additional 199,958 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of VistaGen Therapeutics during the second quarter valued at approximately $190,000. Stempoint Capital LP raised its holdings in VistaGen Therapeutics by 2.0% during the second quarter. Stempoint Capital LP now owns 2,413,254 shares of the company’s stock worth $4,827,000 after purchasing an additional 46,700 shares in the last quarter. AdvisorShares Investments LLC raised its holdings in VistaGen Therapeutics by 27.7% during the second quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company’s stock worth $406,000 after purchasing an additional 44,000 shares in the last quarter. Finally, Occudo Quantitative Strategies LP acquired a new stake in VistaGen Therapeutics in the third quarter worth approximately $152,000. Institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.